FOR IMMEDIATE RELEASE
El Segundo, CA – June 7, 2016 – BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions for life science research and clinical applications, announced today that Ambry Genetics® has migrated its data management, analysis and interpretation of copy number changes to BioDiscovery’s NxClinical software.
Ambry is a CAP-accredited and CLIA-certified leader in clinical genetics diagnostics offering the most comprehensive suite of tests for both inherited and non-inherited disorders. The laboratory performs a significant number of tests per year for analysis of copy number changes and allelic imbalances in neurological disorders and multiple congenital anomalies, and requires a robust data management and interpretation solution to support such high volume operation. NxClinical’s multi-user system with automated and standardized processes and with a central database that automatically creates and augments the in-house case history database nimbly processes samples from Ambry’s high-throughput workflow.
“Ambry Genetics has enjoyed a collaborative relationship with BioDiscovery since we started offering chromosomal microarray analysis in 2009. We are excited to branch into more comprehensive test offerings and manage our rapid growth with NxClinical. The enhanced features will enable Ambry’s clinical lab to provide patients with faster processing and with the same confidence in copy number detection that we have come to rely on from BioDiscovery.” said Dr. ChiaLing Gau, PhD, Executive Laboratory Technical Director, Ambry Genetics.
“We are pleased to continue our relationship with Ambry with their adoption of our latest product, NxClinical. The same trusted algorithms used in BioDiscovery’s Nexus Copy Number software that Ambry has relied upon for years are implemented in the new enterprise system designed specifically for clinical genetic labs. With numerous features in NxClinical to enhance efficiency, Ambry can easily manage its rapid growth in workload without affecting turnaround time.” said Dr. Soheil Shams, CEO, BioDiscovery, Inc.
BioDiscovery’s NxClinical software increases accuracy and efficiency in molecular genetics and cytogenomics labs’ workflows. NxClinical’s platform-independence allows labs to use the same software for analysis and interpretation of data from any technology (e.g. aCGH arrays, SNP arrays, and NGS) allowing much greater flexibility and ease in adopting the best technology for a lab without having to invest additional time and money in installation, training, and validation with a new system. The automated workflows can be customized to mirror a lab’s decision making process and classification terms to pre-classify events, removing repetitive tasks and minimizing potential human error. The system allows enforcement of lab SOPs with assigned user roles and privileges for appropriate user access, extensive audit trail capabilities, and flexible deployment with local or cloud-based options.
Please note the following:
The BioDiscovery software tools referenced are designed to assist clinicians and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.
About Ambry Genetics®
Ambry Genetics is a privately-held healthcare company with the most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases. Since 1999, Ambry has tested nearly one million patient samples benefiting 94% of all U.S. patients covered by public and private insurers. Ambry is dedicated to scientific collaboration by offering its rapidly growing database of anonymized genomic data (variant frequencies) free to the global medical research community to fulfill the promise of the human genome to cure or manage all human disease. Ambry is dedicated to the belief that human health should not be patented or owned, and genomic data should be freely shared so we can try to understand all human disease. For more information about Ambry Genetics, visit http://www.ambrygen.com.
Contact information:Shalini Verma